May 23, 2007
Securities and Exchange Commission
100 F Street, NE
Washington, D.C.
20549
Filed: EDGAR/CORRESP
Dear Sirs and Mesdames,
Re: Comment Letter, dated March 30, 2007 related to
Form 20-F for fiscal year ended May 31, 2006 (the “Comment Letter”) File No. 001-32001
Lorus Therapeutics Inc. hereby notifies the Securities and Exchange Commission that it currently expects to provide responses to the comments contained in the Comment Letter on or before June 15, 2007.
Sincerely,
/s/ Mark Preston
Mark Preston,
Acting Controller
LORUS THERAPEUTICS INC. 2 Meridian Road Toronto, Ontario M9W 4Z7 | T: 416.798.1200 F: 416.798.2200 www.lorusthera.com info@lorusthera.com |